|
1
|
Mejin M, Tiong WN, Lai LYH, Tiong LL,
Bujang AM, Hwang SS, Ong TK and Fong AY: CYP2C19 genotypes and
their impact on clopidogrel responsiveness in percutaneous coronary
intervention. Int J Clin Pharm. 35:621–628. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Oestreich JH, Best LG and Dobesh PP:
Prevalence of CYP2C19 variant alleles and pharmacodynamic
variability of aspirin and clopidogrel in Native Americans. Am
Heart J. 167:413–418. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Shuldiner AR, O'Connell JR, Bliden KP,
Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US,
Gibson Q, et al: Association of cytochrome P450 2C19 genotype with
the antiplatelet effect and clinical efficacy of clopidogrel
therapy. JAMA. 302:849–857. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Levine GN, Bates ER, Blankenship JC,
Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA,
Hollenberg SM, et al: 2011 ACCF/AHA/SCAI Guideline for Percutaneous
Coronary Intervention: A report of the American College of
Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines and the Society for Cardiovascular Angiography
and Interventions. Circulation. 124:e574–e651. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Hamm CW, Bassand J-P, Agewall S, Bax J,
Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al: ESC
Committee for Practice Guidelines: ESC Guidelines for the
management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: The Task Force for the
management of acute coronary syndromes (ACS) in patients presenting
without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J. 32:2999–3054. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fricke-Galindo I, Céspedes-Garro C,
Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López
M, Peñas-Lledó E and LLerena A: Interethnic variation of CYP2C19
alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes
across world populations. Pharmacogenomics J. 16:113–123.
2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sorich MJ, Rowland A, McKinnon RA and
Wiese MD: CYP2C19 genotype has a greater effect on adverse
cardiovascular outcomes following percutaneous coronary
intervention and in Asian populations treated with clopidogrel: A
meta-analysis. Circ Cardiovasc Genet. 7:895–902. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vercellino M, Sànchez FA, Boasi V, Perri
D, Tacchi C, Secco GG, Cattunar S, Pistis G and Mascelli G:
Ticagrelor versus clopidogrel in real-world patients with ST
elevation myocardial infarction: 1-year results by propensity score
analysis. BMC Cardiovasc Disord. 17(97)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wallentin L, Becker RC, Budaj A, Cannon
CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et
al: PLATO Investigators: Ticagrelor versus clopidogrel in patients
with acute coronary syndromes. N Engl J Med. 361:1045–1057.
2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dayoub EJ, Seigerman M, Tuteja S,
Kobayashi T, Kolansky DM, Giri J and Groeneveld PW: Trends in
Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and
Adherence Among Antiplatelet-Naive Patients After Percutaneous
Coronary Intervention, 2008-2016. JAMA Intern Med. 178:943–950.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mega JL, Close SL, Wiviott SD, Shen L,
Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E,
et al: Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med. 360:354–362. 2009.PubMed/NCBI
|
|
12
|
Mega JL, Simon T, Collet J-P, Anderson JL,
Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et
al: Reduced-function CYP2C19 genotype and risk of adverse clinical
outcomes among patients treated with clopidogrel predominantly for
PCI: A meta-analysis. JAMA. 304:1821–1830. 2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mao L, Jian C, Changzhi L, Dan H, Suihua
H, Wenyi T and Wei W: Cytochrome CYP2C19 polymorphism and risk of
adverse clinical events in clopidogrel-treated patients: A
meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis.
106:517–527. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chan NC, Eikelboom JW, Ginsberg JS, Lauw
MN, Vanassche T, Weitz JI and Hirsh J: Role of phenotypic and
genetic testing in managing clopidogrel therapy. Blood.
124:689–699. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hulot J-S, Collet J-P, Silvain J, Pena A,
Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F and Montalescot
G: Cardiovascular risk in clopidogrel-treated patients according to
cytochrome P450 2C19*2 loss-of-function allele or proton pump
inhibitor coadministration: A systematic meta-analysis. J Am Coll
Cardiol. 56:134–143. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Frelinger AL III, Bhatt DL, Lee RD,
Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK,
Barnard MR, et al: Clopidogrel pharmacokinetics and
pharmacodynamics vary widely despite exclusion or control of
polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking,
co-medications (including proton pump inhibitors), and pre-existent
variability in platelet function. J Am Coll Cardiol. 61:872–879.
2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Beitelshees AL, Voora D and Lewis JP:
Personalized antiplatelet and anticoagulation therapy: Applications
and significance of pharmacogenomics. Pharmgenomics Pers Med.
8:43–61. 2015.PubMed/NCBI View Article : Google Scholar
|
